Exciting Updates from Trevi Therapeutics, Inc.

Phase 2b CORAL Trial Reaches 50% Enrollment Milestone

The Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough has reached a significant milestone, with 50% of the participants now enrolled. This is a promising development as the trial progresses towards its completion. The sample size re-estimation results are expected to be announced in December 2024, providing further insights into the efficacy of the investigational therapy, Haduvio™.

Human Abuse Potential (HAP) Study Dosing Complete

Another important update from Trevi Therapeutics, Inc. is the completion of dosing in the Human Abuse Potential (HAP) study. This study is crucial in evaluating the potential for abuse with the investigational therapy, Haduvio™. The topline results of the HAP study are also expected to be revealed in December 2024, shedding light on the safety profile of the medication.

Implications for Chronic Cough Treatment

These updates mark significant progress in the development of Haduvio™ as a potential treatment for chronic cough in patients with IPF and refractory chronic cough. The results of the Phase 2b CORAL trial and the HAP study will provide valuable information that can potentially impact the future management of these conditions.

Impact on Patients

For individuals suffering from chronic cough associated with IPF or refractory chronic cough, the advancements in Trevi Therapeutics’ clinical development programs offer hope for a new treatment option. The potential efficacy and safety of Haduvio™ could provide much-needed relief for patients struggling with these debilitating symptoms.

Global Implications

On a broader scale, the successful completion of the Phase 2b CORAL trial and the HAP study could have far-reaching implications for the field of respiratory medicine. The development of a novel therapy for chronic cough could potentially improve the quality of life for patients worldwide, addressing an unmet medical need in the management of these conditions.

Conclusion

In conclusion, the updates from Trevi Therapeutics, Inc. indicate significant progress in the clinical development of Haduvio™ for the treatment of chronic cough in IPF and RCC. These advancements hold promise for patients seeking relief from these challenging conditions and have the potential to make a meaningful impact on the landscape of respiratory medicine. We look forward to the announcement of the sample size re-estimation results and topline findings in December 2024, as we continue to support innovation in the pursuit of better healthcare outcomes.